Table 2.

General characteristics of included studies

References	Country	Studies’ specificities					Type of economic evaluation	Outcome measure	Study design	Time horizon
		Gender	Age	Early ACLR	CTa/delayed ACLR	Group
Gottlob et al. [12]	USA	M, F	21–27	363	307	Athletes and young people	CUA	QALYs, cost	Model-based	7 years
Farshad et al. [10]	CH	M, F	27.5	229	155	Young people	CUA	QALYs, cost	Model-based	7.5 years
Mather et al. [18]	USA	M, F	26 ± 11	988* + 62**	59	Young people	CUA	QALYs, cost	Model-based	6 years & lifetime
Mather et al. [17]	USA	M, F	26 ± 11	807* + 62**	59	Young people	CUA	QALYs, cost	Model-based	6 years
Kiadaliri et al. [15]	SE	M, F	18–35	61	59	Young people	CUA& CBA	QALYs, cost	Trial based	5 years
Stewart et al. [38]	USA	M, F	Not reported	2719	147	Athletes	CUA	QALYs, cost	Model-based	6 years
Eggerding et al. [8]	NL	M, F	18–65	85	82	young to middle-aged people	CUA	QALYs, cost	Trial based	2 years

CH Switzerland, SE Sweden, NL The Netherlands, QALY quality-adjusted life-year, CUA cost-utility analysis, CBA cost–benefit analysis, early ACLR early anterior cruciate ligament reconstruction surgery, CTa conservative treatment alone, delayed ACLR conservative treatment with optional delayed anterior cruciate ligament reconstruction

^*MOON database, **KANON study